Results 71 to 80 of about 2,823,581 (316)

Clinical Signs of Poisoning with Pyrethroid and Cholinesterase Inhibitors

مجله دانشکده پزشکی اصفهان, 2011
Background: Due to the similarities between clinical signs of toxicity with pyrethroids and cholinesterase inhibitors, if the mistake between these two was made and the patient was treatment with atropine, severe atropine poisoning and even death could ...
Farzad Gheshlaghi, Zohreh Sedighinia
doaj  

Speech Differences between Multiple System Atrophy and Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Delineation of Parkinson's disease (PD) from multiple system atrophy (MSA) can be challenging in early disease stages. Speech characteristics have been studied as digital biomarkers in PD and ataxias. Currently, data on speech in MSA is limited.
Tom Hähnel, Anna Nemitz, Katja Schön, Luise Berger, Annemarie Vogel, Doreen Gruber, Nils Schnalke, Stefan Bräuer, Björn H. Falkenburger, Florin Gandor   +9 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN‐Open‐Label Study

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA (DAXI), a novel botulinum neurotoxin (BoNT) formulation, was shown to be safe, effective, and long‐lasting in the treatment of cervical dystonia (CD) over one treatment cycle in the phase 3, randomized, placebo‐controlled ASPEN‐1 trial.
Peter McAllister, Atul T. Patel, Marta Banach, Aaron Ellenbogen, Jaroslaw Slawek, Sebastian Paus, Hyder A. Jinnah, Virgilio Evidente, Todd M. Gross, Rashid Kazerooni, Conor J. Gallagher, David A. Hollander   +11 more
wiley   +1 more source

Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer’s disease

Journal of Enzyme Inhibition and Medicinal Chemistry, 2017
A novel family of cinnamic acid derivatives has been developed to be multifunctional cholinesterase inhibitors against AD by fusing N-benzyl pyridinium moiety and different substituted cinnamic acids.
Jinshuai Lan, Jian-wei Hou, Yun Liu, Yue Ding, Yong Zhang, Ling Li, Tong Zhang   +6 more
semanticscholar   +1 more source

Health‐Related Quality of Life in Relation to the 5‐2‐1 Criteria in Parkinson's Disease in Sweden

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Device‐aided therapies (DAT) offer alternatives to oral or transdermal dopaminergic treatments in advanced Parkinson's disease (PD), where they can reduce motor fluctuations and dyskinesia and improve health‐related quality of life (HRQoL).
Frida Hjalte, Anna Gustafsson, Jenny Samuelsson, Filip Bergquist, Anders Johansson, Per Odin   +5 more
wiley   +1 more source

Cholinesterase inhibitors for the treatment of delirium in non-ICU settings.

Cochrane Database of Systematic Reviews, 2017
BACKGROUND Delirium is a common clinical syndrome defined as alterations in attention with an additional disturbance in cognition or perception, which develop over a short period of time and tend to fluctuate during the course of the episode. Delirium is
Ailan Yu, Shanshan Wu, Zong-wang Zhang, T. Dening, Sai Zhao, G. Pinner, J. Xia, Daogui Yang   +7 more
semanticscholar   +1 more source

Novel N‐allyl/propargyl tetrahydroquinolines: Synthesis via Three‐component Cationic Imino Diels–Alder Reaction, Binding Prediction, and Evaluation as Cholinesterase Inhibitors

Chemical Biology and Drug Design, 2016
New N‐allyl/propargyl 4‐substituted 1,2,3,4‐tetrahydroquinolines derivatives were efficiently synthesized using acid‐catalyzed three components cationic imino Diels–Alder reaction (70–95%).
Yeray A. Rodríguez, Margarita Gutiérrez, David Ramírez, Jans H. Alzate-Morales, Cristian C. Bernal, Fausto M. Güiza, Arnold R. Romero Bohórquez   +6 more
semanticscholar   +1 more source

The Mild Behavioral Impairment Checklist for Parkinson's Disease: An Ancillary Instrument in Cognitive Assessment

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Mild behavioral impairment (MBI) is a syndrome characterized by the later‐life onset of neuropsychiatric symptoms (NPS) and serves as a potential marker for dementia. In Parkinson's disease (PD), MBI has been associated with worse cognition, cortical atrophy, and altered connectivity.
Gabriel D. Pinilla‐Monsalve, Yuan P. Song, Alexandru Hanganu, Zahinoor Ismail, Oury Monchi   +4 more
wiley   +1 more source

Cholinesterase inhibitors for Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics

Archives of Medical Science, 2007
Introduction: Considering lack of accepted guideline in cases of Parkinson’s disease-related visual hallucinations with poor response or intolerance to antipsychotics, and their possible cholinergic pathogenesis, the trial with cholinesterase inhibitors ...
Tomasz Sobow
doaj  

Cholinergic System Changes in Dopa‐Unresponsive Freezing of Gait in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Freezing of gait (FoG) is a debilitating mobility disturbance that becomes increasingly resistant to dopaminergic pharmacotherapies with advancing Parkinson's disease (PD). The pathophysiology underlying the response of FoG to dopaminergic treatment is poorly understood.
Kelvin L. Chou, Prabesh Kanel, Miriam van Emde Boas, Stiven Roytman, Giulia Carli, Roger L. Albin, Nicolaas I. Bohnen   +6 more
wiley   +1 more source